Olmesartan
- Generic Name
- Olmesartan
- Brand Names
- Azor, Benicar, Benicar Hct, Olmetec, Olmetec Plus, Tribenzor
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N6O3
- CAS Number
- 144689-24-7
- Unique Ingredient Identifier
- 8W1IQP3U10
- Background
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, valsartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
The Confirmatory Olmesartan Plaque Regression Study
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2018-12-24
- Target Recruit Count
- 114
- Registration Number
- NCT01132768
Evaluation of Effects of Exercise Training and ARB in DM Patients
- Conditions
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT01053026
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Olmesartan Comparison to Losartan in Hypertensive Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 941
- Registration Number
- NCT00949884
Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT00914524
Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 304
- Registration Number
- NCT00872586
Olmesartan Medoxomil Versus Losartan in Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2009-07-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 130
- Registration Number
- NCT00857285
- Locations
- 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Chung Shun Medical University Hospital, Taichung City, Taiwan
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 287
- Registration Number
- NCT00856271
Olmesartan on Ambulatory Blood Pressure Change
- Conditions
- Interventions
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2009-03-03
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00854763
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1723
- Registration Number
- NCT00796159
Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 555
- Registration Number
- NCT00759551
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.